Education
Level 1: Physique EssentialsApplied Hypertrophy Optimization (AHO)Female Physique Module
Training Programs
X-Frame ProgramHourglass Program
Coaching
Apply for Coaching
Community
J3U Hub (Free)Applied LabAffiliate Program
More
BlogMerch
Student portal Join Now
‹ All articles
Bodybuilding

Episode 33: Prophylactic Series: Why Telmisartan in Enhanced Competitors?

Episode 33: Prophylactic Series: Why Telmisartan in Enhanced Competitors?

In this episode of J3 University, Luke and I discuss the risk of PED usage and how blood pressure medications serve as a hard reduction strategy. All blood pressure medications are covered and specially answering why Telmisartan is spoken about more frequently. 

Timestamps

NPC Nationals and Pro Card Wins- 00:00:08

Enhanced Bodybuilder Risk- 00:03:10

Renin-angiotensin-aldosterone system, Classes of Medication- 00:07:52

ARB vs ACE Inhibitors- 00:13:31

Telmisartan Actions/Benefits- 00:15:15

Blood viscosity/blood dump, Improvement in lab work- 00:19:14

Access to medication- 00:24:36

Deploying for reduction in Water retention- 00:29:46

Where to find more info- 00:34:00

Episode Available On: YouTube, Spotify, Google Play, iTunes

Like, Share, Subscribe

LINK in BIO
#J3University

Take the guesswork out of your physique

J3U Level 1 gives you the full science based system for training, nutrition, and PED strategy. Or join the free J3U Hub and start learning today.

More from Bodybuilding
Bodybuilding

How to Pre-Exhaust for MORE Muscle Growth

How to Pre-Exhaust for MORE Muscle Growth In the realm of bodybuilding, pre-exhaust session has been a classic technique…

John JewettJuly 15, 2024
Bodybuilding

Stopping Strenght Loss on Prep Immediately

Training is the biggest tool you have to hold muscle tissue on prep. If load and reps or quality of stimulus (execution …

John JewettJuly 9, 2024
Bodybuilding

Hiding Loose Skin on Stage

This week I wanted to share with you a posing strategy I like to employ for helping clients hide loose skin in their abd…

John JewettJune 10, 2024